Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasms 4Recurrence 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Respiratory Aspiration 2Myelodysplastic Syndromes 2Liver Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Postoperative Complications 1Postoperative Cognitive Complications 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell 1Lymphatic Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Immunologic Deficiency Syndromes 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy 1Delirium 1

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Injections × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡